Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
With
Medivation, Inc.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed prostate cancer (all stages) for whom androgen deprivation therapy is indicated (except when indicated in a neoadjuvant/adjuvant therapy)
Asymptomatic from prostate cancer
Non-castrate level of testosterone (≥ 8 nmol/L (230 ng/dL)) at screening
PSA ≥ 2 ng/mL at screening
You may not be if
Has previously or is currently receiving:
Hormonal therapy with intent to treat prostate cancer
Systemic glucocorticoids
Chemotherapy with the intent to treat prostate cancer
Opiate analgesics for pain from prostate cancer
Radiation therapy for treatment of the primary tumor or metastases
Has history of known or suspected brain or skull metastases or leptomeningeal disease
Has history of seizure including febrile seizure or any condition that may predispose to seizure or history of loss of consciousness or transient ischemic attack
Clinically significant cardiovascular disease
Clareo Health | A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy
